These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3268894)

  • 1. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia.
    Ralston SH; Alzaid AA; Gallacher SJ; Gardner MD; Cowan RA; Boyle IT
    Q J Med; 1988 Oct; 68(258):825-34. PubMed ID: 3268894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
    Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
    Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
    Davis JR; Heath DA
    Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH; Alzaid AA; Gardner MD; Boyle IT
    Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
    Walls J; Ratcliffe WA; Howell A; Bundred NJ
    Br J Cancer; 1994 Jul; 70(1):169-72. PubMed ID: 8018531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.
    Cantwell BM; Harris AL
    Br Med J (Clin Res Ed); 1987 Feb; 294(6570):467-9. PubMed ID: 3103730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
    Coleman RE; Rubens RD
    Br J Cancer; 1987 Oct; 56(4):465-9. PubMed ID: 3689664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An audit of the management of malignant hypercalcaemia.
    Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
    Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
    Sawyer N; Newstead C; Drummond A; Cunningham J
    Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
    Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
    J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
    Yates AJ; Murray RM; Jerums GJ; Martin TJ
    Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypercalcaemia in thyrotoxicosis with aminohydroxypropylidene diphosphonate.
    Tan TT; Alzaid AA; Sutcliffe N; Gardner MD; Thomson JA; Boyle IT
    Postgrad Med J; 1988 Mar; 64(749):224-7. PubMed ID: 3174541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow up of breast cancer patients treated for hypercalcaemia with aminohydroxypropylidene bisphosphate (APD).
    Grutters JC; Hermus AR; de Mulder PH; Beex LV
    Breast Cancer Res Treat; 1993; 25(3):277-81. PubMed ID: 8369528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
    Coukell AJ; Markham A
    Drugs Aging; 1998 Feb; 12(2):149-68. PubMed ID: 9509293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
    Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR
    Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.